Allen Mia I, Rahimi Omeed, Johnson Bernard N, Cao Jianjing, Newman Amy Hauck, Nader Michael A
Department of Translational Neuroscience, Wake Forest University School of Medicine, Winston-Salem, North Carolina.
Medicinal Chemistry Section, Molecular Targets and Medications Discovery Branch, National Institute on Drug Abuse-Intramural Research Program, National Institutes of Health, Baltimore, Maryland.
J Pharmacol Exp Ther. 2025 Jan;392(1):100033. doi: 10.1124/jpet.124.002356. Epub 2024 Nov 22.
Despite considerable efforts, there remains no Food and Drug Administration-approved medications for cocaine use disorder. One strategy to mitigate cocaine craving and relapse is to elevate dopamine. The dopamine transport inhibitor and releaser d-amphetamine has been shown to decrease cocaine self-administration (SA), although it has abuse liability. Recently, several modafinil analogs reduced cocaine SA in rats and monkeys, including JJC8-088, characterized as "cocaine-like" in rats, and JJC8-091, characterized as "atypical" and not SA by rats. The present study evaluated the reinforcing effects of both compounds in monkeys under several conditions. For experiment 1, 4 male cocaine-experienced rhesus monkeys self-administered cocaine (0.001-0.3 mg/kg per injection), JJC8-088 (0.001-0.3 mg/kg per injection), and JJC8-091 (0.1-3.0 mg/kg per injection) under a progressive-ratio schedule of reinforcement. Both JJC compounds functioned as reinforcers with equal reinforcing strength to cocaine. Although JJC8-091 was less potent than cocaine, JJC8-088 and cocaine had similar potencies. For experiment 2, 1 male and 2 female drug-naïve cynomolgus monkeys responded on a fixed-ratio schedule of food reinforcement. JJC8-091 was self-administered at rates higher than saline in all 3 monkeys. In experiment 3, monkeys from experiment 2 responded under a concurrent drug versus food choice paradigm and given access to cocaine or JJC8-091 under these conditions. At doses equal to or one-half log-units higher than doses used in experiment 2, cocaine, but not JJC8-091, was chosen over food. Together, these results demonstrate that although JJC8-091 may be reinforcing under some conditions, its reinforcing strength, in the presence of an alternative reinforcer, is substantially less than cocaine. SIGNIFICANCE STATEMENT: JJC8-088 and JJC8-091 have shown efficacy is reducing cocaine self-administration (SA) in rats and in nonhuman primates. This study found that both compounds maintained SA in monkeys responding under several conditions. However, when given access to an alternative reinforcer during the SA session, JJC8-091 was not reinforcing, suggesting that JJC8-091 may have lower abuse liability than cocaine and may be a viable candidate for cocaine use disorder because, in the human population, alternatives to drug use are often available.
尽管付出了巨大努力,但美国食品药品监督管理局(FDA)仍未批准用于治疗可卡因使用障碍的药物。减轻对可卡因的渴望和复吸的一种策略是提高多巴胺水平。多巴胺转运抑制剂和释放剂右旋苯丙胺已被证明可减少可卡因自我给药(SA),尽管它具有滥用可能性。最近,几种莫达非尼类似物在大鼠和猴子中降低了可卡因SA,包括在大鼠中被表征为“可卡因样”的JJC8 - 088,以及在大鼠中被表征为“非典型”且不会导致自我给药的JJC8 - 091。本研究评估了这两种化合物在多种条件下对猴子的强化作用。在实验1中,4只曾接触过可卡因的雄性恒河猴在渐进比率强化程序下自我给药可卡因(每次注射0.001 - 0.3毫克/千克)、JJC8 - 088(每次注射0.001 - 0.3毫克/千克)和JJC8 - 091(每次注射0.1 - 3.0毫克/千克)。两种JJC化合物均起到强化物的作用,其强化强度与可卡因相当。尽管JJC8 - 091的效力低于可卡因,但JJC8 - 088和可卡因的效力相似。在实验2中,1只雄性和2只未接触过药物的雌性食蟹猴在固定比率食物强化程序下做出反应。在所有3只猴子中,JJC8 - 091的自我给药速率高于生理盐水。在实验3中,实验2中的猴子在药物与食物的同时选择范式下做出反应,并在这些条件下可获得可卡因或JJC8 - 091。在等于或比实验2中使用的剂量高半个对数单位的剂量下,猴子选择了可卡因而非JJC8 - 091。综合来看,这些结果表明,尽管JJC8 - 091在某些条件下可能具有强化作用,但其在存在替代强化物的情况下的强化强度远低于可卡因。重要声明:JJC8 - 088和JJC8 - 091已显示出在大鼠和非人类灵长类动物中降低可卡因自我给药(SA)的功效。本研究发现,这两种化合物在多种条件下使猴子保持自我给药行为。然而,在自我给药期间给予替代强化物时,JJC8 - 091没有起到强化作用,这表明JJC8 - 091的滥用可能性可能低于可卡因,并且可能是治疗可卡因使用障碍的一个可行候选药物,因为在人群中,往往存在药物使用的替代方式。